IBIS Therapeutics
William Glauser has a diverse work experience spanning over several companies. William is currently the Senior Vice President of Business Strategy at XtalPi Inc. since February 2020. Prior to that, they were the Scientific Co-Founder at Ibis Therapeutics starting from March 2018. From May 2017 to February 2020, William held the role of Senior Partner at IOI Partners LLC. Earlier, from January 2016 to May 2017, they worked as the Senior Vice President of Commercial Operations at Seven Bridges, where they introduced innovative product lines and advised the President and CSO on business and market development strategies. Lastly, William served as the Senior Vice President of Business Development at Schrödinger from 1995 to 2015.
William Glauser holds a Master of Business Administration (M.B.A.) with a focus on Entrepreneurship/Entrepreneurial Studies from North Carolina State University. William also has a Postdoctoral Fellowship in Theoretical Chemistry from the University of California, Berkeley. Additionally, William Glauser earned a Doctor of Philosophy (PhD) in Physical Chemistry from the University of South Florida and obtained a Bachelor of Science (BS) in Chemistry from Dickinson College. In terms of certifications, they completed the Executive Data Science Specialization from Johns Hopkins University through Coursera in June 2017.
This person is not in any teams
This person is not in any offices
IBIS Therapeutics
Ibis is defining the future of precision by guiding drugs toward beneficial on-targets and away from harmful off-targets. Its AI-driven Molecular Fingerprint™ Platform engine enables valuable insights into information about drug candidates with the potential for maximum efficacy and safety. Transcending the one disease-one target-one drug paradigmallows the Ibis platform to integrate polypharmacology, selectivity profiling, safety assessments, and drug repurposing into a coherent framework applicable to all stages of drug discovery and development.